• Novogenia launched its MGT Plus methylation genetic test in the U.S. through its partnership with 10X Health.
• The rollout expands the pair’s joint product pipeline, targeting genetic analysis and longevity-focused services.
• MGT Plus broadens methylation screening to 27 genes across six pathways, aiming to differentiate from narrower commercial tests.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novogenia AG published the original content used to generate this news brief on August 25, 2026, and is solely responsible for the information contained therein.